Advaxis Interest Expense 2011-2025 | ADXS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Advaxis

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
28 K	74 K	-	-	-7 K	-63 K	-82 K	-201	-6.6 K	5.25 K	988 K	4.54 M	4.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.7 M	-82 K	925 K

Quarterly Interest Expense Advaxis

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-4 K	-	-	-1 K	12 K	-	229 K	217 K	-	-2 K	-1 K	-	-4 K	-	-	-2 K	-35 K	-42 K	-2 K	-6 K	-123	-75 K	-72 K	-3.35 K	-4	-	-201	-197	6.24 K	-6.6 K	34.9 K	-6.6 K	2.02 K	5.25 K	5.25 K	3.24 K	361 K	600 K	143 K	96 K	1.62 M	4.24 M	1.05 M	1.58 M	532 K	2.72 M	1.77 M	419 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.24 M	-75 K	384 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Aptevo Therapeutics APVO	472 K	$ 0.56	-7.58 %	$ 155 K	USA
Aclaris Therapeutics ACRS	2.95 M	$ 3.03	-	$ 234 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.19	0.63 %	$ 7.68 B	Australia
Autolus Therapeutics plc AUTL	9.29 M	$ 1.82	8.68 %	$ 464 M	Britain
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 210.42	0.69 %	$ 5 B	Danmark
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
BioVie BIVI	4.3 M	$ 1.19	-2.07 %	$ 1.76 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.19	-13.09 %	$ 413 M	Israel
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 12.31	-0.32 %	$ 810 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.88	-0.89 %	$ 1.3 B	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Certara CERT	-15.5 M	$ 8.87	-0.22 %	$ 1.42 B	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Cellectis S.A. CLLS	371 K	$ 4.92	3.47 %	$ 116 M	France
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Axon Enterprise AXON	286 M	$ 580.25	-0.61 %	$ 44 B	USA
Aytu BioScience AYTU	-512 K	$ 2.49	1.43 %	$ 15.6 M	USA
ChromaDex Corporation CDXC	3 K	-	-0.88 %	$ 598 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Celldex Therapeutics CLDX	927 K	$ 26.01	-1.5 %	$ 1.67 M	USA